RESUMEN
The Altai orogen is a typical intracontinental orogen in Central Asia that experienced far-field deformation associated with Indian-Eurasian plate convergence. This region is characterized by uplift comparable to that of the Tianshan Mountains but has a distinct strain rate. Half of the Indo-Asia strain is accommodated by the Tianshan Mountains, whereas the Altai Mountains accommodates only 10%. To elucidate how the Altai Mountains produced such a large amount of uplift with only one-fifth of the strain rate of the Tianshan Mountains, we constructed a detailed crustal image of the Altai Mountains based on a new 166.8-km deep seismic reflection profile. The prestack migration images reveal an antiform within the Erqis crust, an â¼10 km Moho offset between the Altai arc and the East Junggar area, and a major south-dipping (30° dip) thrust in the lower crust beneath the Altai Mountains, which is connected to the Moho offset. The south-dipping thrust not only records the southward subduction of the Ob-Zaisan Ocean in the Paleozoic but also controlled the Altai deformation pattern in the Cenozoic with the Erqis antiform. The Erqis antiform prevented the extension of deformation to the Junggar crust. The south-dipping thrust in the lower crust of the Altai area caused extrusion of the lower crust, generating uplift at the surface, thickening of the crust, and steep (â¼10 km) Moho deepening in the Altai Mountains. This process significantly widened the deformation zone of the Altai Mountains. These findings provide a new geodynamic model for describing how inherited crustal structure controls intraplate deformation without strong horizontal stress.
RESUMEN
Background: Myasthenia gravis (MG) is an acquired autoimmune disease. The main clinical features of MG are skeletal muscle fatigue and pathological fatigue, which worsen at night or after fatigue, such as dyspnea, dysphagia, and systemic weakness. Plasma exchange (PE) is often used in patients with acute exacerbation of MG. Intravenous immunoglobulin (IVIG) is a collection of immunoglobulins from thousands of donors. IVIG can replace a variety of immunosuppressants or PE. However, the effect of PE or IVIG on patients' consciousness, immune function, and prognosis is not clear. Objective: A prospective randomized test of the effects of PE combined with immunoglobulin on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis (MGC). Methods: Sixty patients with MGC treated from February 2019 to April 2021 were enrolled in our hospital. The cases who received PE were set as the PE group, and those who received PE combined with immunoglobulin were set as the PE+immunoglobulin group. The efficacy, clinical score, state of consciousness, immune function, acetylcholine receptor antibody (AChR-Ab), lymphocyte (LYM), albumin (ALB) levels, and the incidence of adverse reactions were compared. Results: The improvement rate was 100.005% in the treatment group and 83.33% in the PE group. After treatment, the clinical score of the PE+immunoglobulin group was lower than that of the PE group, and the clinical relative score of the PE+immunoglobulin group was higher than that of the PE group (P < 0.05). The number of conscious people in the PE+immunoglobulin group was more than that in the PE group (P < 0.05). Immunoglobulin A, immunoglobulin M, immunoglobulin G, and immunoglobulin G in the PE+immunoglobulin group were higher than those in the PE group (P < 0.05). The levels of AChR-Ab and ALB in the PE+immunoglobulin group were higher than those in the PE group, while the level of LYM in the PE+immunoglobulin group was lower than that in the PE group. The incidence of skin system, gastrointestinal system, nervous system, and systemic damage in the PE+immunoglobulin group was lower than that in the PE group (P < 0.05). Conclusion: The treatment of MGC with PE combined with immunoglobulin can not only effectively enhance the consciousness and immune function of patients but also effectively promote the prognosis, and the safety of treatment can be guaranteed.